Pyxis Oncology, Inc. announced it will present new, positive preclinical data highlighting micvotabart pelidotin (MICVO, formerly PYX-201) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, from April 25 to 30, 2025. These data further elucidate the innovative mechanism of action of MICVO, a first-in-concept antibody-drug conjugate targeting EDB+FN.
The preclinical findings include expression data from patient-derived xenograft (PDX) mouse models exposed to MICVO, which indicate gene signatures associated with efficacy and deepen the understanding of its mechanism of action. Furthermore, a combination of a mouse analog of MICVO and a mouse anti-PD-1 therapy in a syngeneic model resulted in significantly greater tumor regression than either treatment alone.
The company continues to advance MICVO into monotherapy and combination clinical trials, targeting recurrent and metastatic head and neck squamous cell carcinoma. Preliminary data from these trials are expected in the second half of 2025 and the first half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.